Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory. Our mission is to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions through RNA splicing analytics and artificial intelligence. We focus on the discovery of RNA therapeutics. Over 30 million people in the US suffer from genetic diseases or cancer that could be caused by mutations affecting RNA splicing. 370 human diseases are known to be caused by splicing errors, and more remain to be discovered.
Our breakthrough technology, SpliceCore, is a cloud-based platform that is experimentally validated to predict drug targets and biomarkers through splicing discovery from RNA-seq data, using Artificial Intelligence. We are using our software to identify splicing errors causative of diseases, identify the right drug-targets and develop RNA therapeutics through partnerships and collaborations with Biopharma. Our in-silico RNA therapeutics discovery platform replaces expensive drug-target selection and lead design with efficient computer simulations, decreasing time, cost, and failure risk of drug development programs.
Total Funding: $5,600,000
Funding Stage: Funded
Business Stage: Scaling Up
Market: B2B
Company Size: 26 to 50
Founded: 2014
For AI Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI Startup founders or founders at Envisagenics
Bioinformatics Scientist
New York, New York
Senior Data Scientist
New York, New York
Business Development Associate
New York, New York
Bioinformatics Analyst
New York, New York
Envisagenics - AI Startup | AI Startup Profile Powered by Appengine AI | Appengine AI - AI Ecosystem of 12,000+ AI Startups
Envisagenics - Manage Profile
World's Most Promising AI Startups
World's Leading AI Ecosystem of AI Startups, Founders, Investors, and AI Professionals
Get Started